Tamoxifen therapy in a murine model of myotubular myopathy-Reference-Cited by-同舟云学术

Tamoxifen therapy in a murine model of myotubular myopathy

Published:2018-11-19 Issue:1 Volume:9 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Maani Nika,Sabha Nesrin,Rezai Kamran^ORCID,Ramani Arun,Groom Linda,Eltayeb Nadine,Mavandadnejad Faranak,Pang Andrea,Russo Giulia^ORCID,Brudno Michael,Haucke Volker,Dirksen Robert T.,Dowling James J.

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-018-07057-5.pdf

Reference58 articles.

1. Amburgey, K. et al. A natural history study of X-linked myotubular myopathy. Neurology 89, 1355–1364 (2017).

2. Lawlor, M. W. et al. Skeletal muscle pathology in X-linked myotubular myopathy: review with cross-species comparisons. J. Neuropathol. Exp. Neurol. 75, 102–110 (2016).

3. Laporte, J. et al. A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast. Nat. Genet. 13, 175–182 (1996).

4. Ketel, K. et al. A phosphoinositide conversion mechanism for exit from endosomes. Nature 529, 408–412 (2016).

5. Dowling, J. J. et al. Myotubular myopathy and the neuromuscular junction: a novel therapeutic approach from mouse models. Dis. Model Mech. 5, 852–859 (2012).

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Skeletal muscle: molecular structure, myogenesis, biological functions, and diseases;MedComm;2024-07

2. Neuromuscular diseases and long-term ventilation;The Transition of Respiratory Care: from Child to Adult;2024-06-01

3. Molecular mechanisms and therapeutic strategies for neuromuscular diseases;Cellular and Molecular Life Sciences;2024-04-28

4. Characterization of a novel zebrafish model ofMTMR5-associated CMT4B3;2024-04-20

5. Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial;The Lancet Neurology;2023-12